Natera CFO touts record Signatera volumes and raised outlook, but operating leverage remains unproven pending Q2 financials

What happened

At the Canaccord conference, Natera CFO Mike Brophy highlighted record Signatera volumes and raised the company's outlook, citing continued revenue and ASP strength, improved gross margins, and narrowing losses across women's health, oncology, and organ health. This presentation comes after Q1 2026 results showed revenue growth of 38.8% YoY to $696.6M but an operating loss that widened to $(93.5)M on accelerated R&D and SG&A spending, which had driven the prior WAIT rating. The new commentary suggests management believes operating leverage is now emerging, but conference remarks lack the granularity of reported financials and may reflect selective disclosure. The company also faces increasing competitive pressure from Labcorp and Foundation Medicine in the MRD space, which could temper pricing and volume growth. Investors should await the official Q2 2026 10-Q filing to verify whether narrowing losses and gross margin improvements are substantiated.

Implication

The positive commentary at Canaccord reduces the immediate downside risk from the Q1 operating loss spike, but until reported numbers validate it, the thesis remains unchanged. The key test is whether operating loss narrows sequentially and opex growth decelerates relative to revenue; if confirmed, the stock's attractive entry near $190 could be raised. Conversely, if Q2 results show continued opex outpacing revenue, the bear case becomes more likely. Competitive dynamics with Foundation Medicine's Medicare-covered MRD test require monitoring for any impact on ASP or volume growth. The raised outlook suggests management is confident, but we need to see the actual financial statements to separate genuine improvement from conference spin.

Thesis delta

Thesis unchanged pending confirmation; if Q2 results confirm narrowing losses, we would upgrade to a more constructive stance and consider accumulation near current levels. The raised outlook and improved margin commentary reduce the probability of the bear case, but the operating leverage inflection is not yet proven.